Albius Sciences Group
We are the pre-clinical stage biotech platform specialised in rapid discovery of small molecule drugs.
We started as the “spin-off” of the In Silico drug design research programme from the Oita University, Japan.
With our In Silico design methodology, we have been creating new small molecule drugs with entirely different chemical structures with promising bio-activities.
In our compound library, we have candidates showing effects like:
Anti-viral | Anti-fibrotic | Anti-cancer
To date, our most promising candidates are targeting:
Coronaviruses* | Fibrosis | RSV | Rabies
(*on human and other animals like feline and swine.)
Our Journey
Our In Silico drug discovery originated in Japan where the technology and methodology were first pioneered and developed by Prof. Shigeru Matsuoka (also our CTO) and his team of research scientists and technicians.
In 2021, we established Albius Hong Kong and then entered into HKTSP IncuBio Programme in 2022.
In early 2023, we established Albius Singapore as our Group HQ & IP Centre.
In summer 2023, we established Albius Austria as our Europe HQ and activated Albius China.